Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | POLA1 | P09884 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | DGKA | P23743 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31049868 | 1.00 | TSHR (0.67) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL4006166 | 1.00 | TSHR (0.67) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL11849992 | 1.00 | TSHR (0.67) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL16719251 | 1.00 | TSHR (0.67) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL1115015 | 1.00 | TSHR (0.67) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL8973175 | 1.00 | TSHR (0.67) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL1365853 | 1.00 | TSHR (0.67) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL1285241 | 1.00 | TSHR (0.67) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL454130 | 1.00 | TSHR (0.67) | TSHRLMNAALDH1A1L3MBTL1KMT2A | |
| SCHEMBL31734806 | 1.00 | TSHR (0.67) | TSHRLMNAALDH1A1L3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 400 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118955371-A | HDAC inhibitor containing quinoline structure, and preparation method and application thereof | 新乡医学院 | 2024-11-15 | — | — | CN | claimed |
| CN-118619922-A | Hydroxamic acid compound, and preparation method and application thereof | 郑州大学 | 2024-09-10 | — | — | CN | claimed |
| CN-118047678-A | Synthesis method of 7-methyl bromoheptanoate | 海门瑞一医药科技有限公司 | 2024-05-17 | — | — | CN | claimed |
| CN-111362942-B | Sophoridine derivative with multi-target anti-tumor activity and preparation method and application thereof | 天津市医药科学研究所 | 2022-07-05 | — | — | CN | claimed |
| CN-107619407-B | Bis- target spot inhibitor of HDAC and VEGFR based on pazopanib structure and its preparation method and application | 山东大学 | 2019-05-24 | — | — | CN | claimed |
| US-4163106-A | Prostaglandin precursors and processes for preparing the same | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1979-07-31 | — | — | US | claimed |
| EP-4747239-A1 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4746874-A2 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-122055150-A | Cyproheptadine derivatives | 思凯生科股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260124271-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERS | VIKING THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260097126-A1 | PHARMACEUTICAL FORMULATIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERS | VIKING THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-3993773-A | Control of mites with esters of cyclopropane substituted carboxylic acids | ZOECON CORPORATION (US) | 1976-11-23 | — | — | US | disclosed |
| US-3987081-A | ALKYL DERIVATIVES OF PROSTANOIC ACIDS AND PREPARATION THEREOF | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-10-19 | — | — | US | disclosed |
| US-3969384-A | Esters of cyclopropane alkanoic acids | ZOECON CORPORATION (US) | 1976-07-13 | — | — | US | disclosed |
| US-3966764-A | ELECTRON SPIN RESONANCE | SYVA COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
| US-3966744-A | Spin labeled compounds | SYVA COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
| US-3960907-A | MITICIDES | ZOECON CORPORATION (US) | 1976-06-01 | — | — | US | disclosed |
| US-3959287-A | Ligand determination of spin labeled compounds by receptor displacement | SYVA COMPANY (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | TSHR 1810/4885LMNA 3498/4885ALDH1A1 1304/4885 |
| US-20260124271-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERS | GLP1R, GIPR, GPR119 | TSHR 46/4885LMNA 3834/4885ALDH1A1 2456/4885 |
| US-20260097126-A1 | PHARMACEUTICAL FORMULATIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERS | GIPR, GLP1R, GPR119 | TSHR 59/4885LMNA 3839/4885ALDH1A1 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.